You are here

NCI-Designated Cancer Centers Endorse New HPV Vaccine Recommendations

Statement supports fewer vaccinations, urges action to increase vaccination rates

As national vaccination rates for the human papillomavirus (HPV) remain low, the University of Texas MD Anderson Cancer Center has united with the 68 other National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement endorsing recently revised vaccination recommendations from the Centers for Disease Control and Prevention (CDC).

The new CDC guidelines recommend 11- to 12-year-old boys and girls receive two doses of the nine-valent HPV vaccine at least six months apart. Adolescents and young adults 15 years of age and older should continue to complete the three-dose series.

“This collaborative effort is a tremendous opportunity to raise awareness of these new recommendations and the importance of HPV vaccination, knowing that most people will be exposed to HPV at some point in their lives,” said Lois Ramondetta, MD, Professor of Gynecologic Oncology and Reproductive Medicine. “We hope that requiring two shots instead of three will make it easier for children to be vaccinated, bringing rates closer to the Healthy People 2020 goal of 80%.”

The CDC reports that incidence rates of HPV-associated cancers continue to rise, with approximately 39,000 new HPV-associated cancers now diagnosed each year in the United States. Although HPV vaccines can prevent the majority of cervical, anal, oropharyngeal (middle throat), and other genital cancers, vaccination rates remain low.

Across the U.S., just 41.9% of girls and 28.1% of boys are completing the recommended vaccine series, according to a 2015 CDC report. In Texas, vaccination rates are even lower, with only 40.9% of girls and 24% of boys completing the vaccine series.

“In the spirit of the White House Cancer Moonshot, we must continue to work collaboratively to take advantage of effective cancer prevention strategies that can save thousands of lives in the future,” said Ernest Hawk, MD, Vice President and Division Head of Cancer Prevention and Population Sciences.

Through its HPV-related Cancers Moonshot Program, established in 2015, MD Anderson has made a commitment to reducing the incidence and mortality of HPV-related malignancies by raising awareness and identifying practical solutions to improve vaccination rates. MD Anderson’s program is a novel organizational model designed to more rapidly convert scientific discoveries into life-saving advances.

“Research indicates several barriers limit acceptance of the vaccine, including inadequate parental education and a lack of strong recommendations from health care providers,” said Ramondetta, who is also co-lead of the moonshot. “As oncologists who routinely witness the devastating effects of these diseases, we urge all pediatricians to recommend HPV vaccinations and prevent their patients from becoming our patients.”

Recognizing the need for collective action to overcome these barriers, NCI-designated cancer centers have organized an ongoing series of national summits to share research findings and discuss best practices for improving vaccination rates.

The current endorsement is the result of discussions from a summit hosted this summer by The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Approximately 150 experts from across the country gathered in Columbus to present research updates and plan future collaborative actions across NCI-designated cancer centers.

Source: The University of Texas MD Anderson Cancer Center; January 11, 2017.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs